Attendee search 

Datatrial is an oncology-focused boutique clinical data organization that provides the reliability of a big company, but the personalized service and flexibility of a more nimble provider. Whether you want your study conducted in paper or through our own innovative eClinical technologies, we design your study with insight and expertise, backed by comprehensive data management, bio-statistical and consulting services. By bridging the gap between the promise of outsourcing and the way results are delivered, we make your clinical study less of a trial.

Come and see us at booth #72

Datatrial is an oncology-focused boutique clinical data organization that provides the reliability of a big company, but the personalized service and flexibility of a more nimble provider. Whether you want your study conducted in paper or through our own innovative eClinical technologies, we design your study with insight and expertise, backed by comprehensive data management, bio-statistical and consulting services. By bridging the gap between the promise of outsourcing and the way results are delivered, we make your clinical study less of a trial.

Come and see us at booth #72

BioPartner.co.uk is an independent, accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. BioPartner's UK Delegations promote the UK presence at major international biopharma conferences. Through the BioPartnership Programme, BioPartner assists companies to attend these events by providing access to government grants and heavily discounted entry fees.

Come and see us at booth #73

Vivacta is developing a unique monitoring system to measure patient outcomes in real time at the point-of-care, whether in the hospital, in physician offices or at home. For chronic therapies, regular near-patient monitoring of drug levels and drug response allows faster therapy adjustment and longer periods within therapeutic range, leading to improved clinical and economic outcomes of interest to reimbursement agencies. The system, which uses revolutionary piezofilm technology but which requires no sample preparation, puts the precision and performance of lab-based analysers at the disposal of non-expert users including patients themselves. In a world where clinical and economic outcomes increasingly drive reimbursement of new therapies and affect re-appraisal of established treatments, the simple-to-use Vivacta desktop device has the potential to revolutionise the personalisation of pharmaceutical care.

Vivacta is a privately-held, venture capital-backed medical diagnostic company developing its proprietary piezofilm technology to achieve extremely high sensitivity and dynamic range for a new generation of diagnostic and monitoring products adapted to near-patient testing. The company's system has been validated for large molecules such as proteins as well as small molecule drugs and provides actionable information to users in 5-10 minutes. Beyond diagnosis of disease, the platform has significant utility in the monitoring of drug levels simultaneously with the monitoring of drug response (measuring biomarkers of drug response, disease response or other pharmacodynamic measures, including anti-drug antibodies or other prognostic measures). While the system also has the potential to measure nucleic acid analytes, useful in the pharmacogenomic prediction of patient response to therapy, the system’s broader applications in personalised medicine arise from its capacity to measure protein and small molecule analytes, rapidly and locally.

come see us at booth #73

Competitive Drug Development International is an international biotechnology and pharmaceutical consulting company. Unlike a traditional consultancy who talk and advise, our mode of working is hands-on and delivery focused, in addition to the strategic planning. From evidence based protocol feasibility, to management of CROs and CMOs, to delivery of POC, we can achieve your specific objectives quickly and more cost-effectively. Come and see us at Bio-Europe 2012 in Hamburg at booth #27.

Selcia Limited is a leading worldwide provider of contract research services. Our headquarters are in Ongar, Essex and we have a branch in Hopkinton, MA. Selcia operates two divisions, Selcia Discovery, which provides integrated small molecule drug discovery to pharmaceutical and biotech clients, and Selcia Radiolabeling which specializes in 14C GMP radiolabelling.

In addition to general medicinal chemistry and biology capabilities applicable across a range of target classes, Selcia Discovery has particular strengths in three unique and highly synergistic technologies:
(1) medicinal chemistry of complex natural products
(2) capillary electrophoresis-based fragment and natural product screening
(3) PPI targets in particular peptidyl-prolyl isomerase targets (including cyclophilins, FKBPs, Pin1, together called PPIases).
Whilst relatively neglected by pharmaceutical companies in the past, understanding of the involvement of PPIases in many diseases is currently emerging. All PPIase inhibitors presently in clinical use or in development are natural products, natural product derivatives or have structures inspired by natural products.

The combination of these technologies has enabled Selcia to deliver several clinical PPIase inhibitors to clients, but has also generated IP for Selcia, which we have recently demerged into a new company, Mitopharm Limited who are in advanced license negotiations for a breakthrough drug in the field of acute and chronic neurodegenerative diseases. Other applications in the fields of chronic inflammatory diseases, oncology, COPD, and virus infections will be developed by Mitopharm either via investment or via joint R&D programs with pharmaceutical companies.

We have also recently established Selcia Pharma, a spin out company focussed on the optimisation/preclinical development and partnering of Selcia’s preclinical antimicrobial (antibacterial & antifungal) assets.

Come and see us at booth #73